DLD Asset Management LP Has $888,000 Stock Position in Surmodics, Inc. $SRDX

DLD Asset Management LP reduced its position in Surmodics, Inc. (NASDAQ:SRDX) by 37.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,881 shares of the company’s stock after selling 17,987 shares during the period. DLD Asset Management LP owned about 0.21% of Surmodics worth $888,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Surmodics by 705.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $37,000 after purchasing an additional 1,080 shares during the period. Creative Planning acquired a new stake in shares of Surmodics in the second quarter worth $318,000. Thompson Davis & CO. Inc. acquired a new stake in shares of Surmodics in the second quarter worth $1,873,000. Geode Capital Management LLC grew its holdings in shares of Surmodics by 0.3% during the second quarter. Geode Capital Management LLC now owns 336,239 shares of the company’s stock valued at $9,992,000 after buying an additional 1,128 shares in the last quarter. Finally, Quinn Opportunity Partners LLC raised its position in Surmodics by 7.0% during the second quarter. Quinn Opportunity Partners LLC now owns 122,521 shares of the company’s stock valued at $3,640,000 after buying an additional 8,000 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Stock Up 0.4%

SRDX opened at $42.98 on Thursday. The company has a market capitalization of $614.53 million, a PE ratio of -34.94 and a beta of 1.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.91 and a quick ratio of 3.10. Surmodics, Inc. has a fifty-two week low of $25.87 and a fifty-two week high of $43.00. The business has a 50-day moving average of $31.98 and a 200-day moving average of $31.93.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SRDX. Zacks Research upgraded Surmodics to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surmodics in a research report on Wednesday, October 8th. Finally, Barrington Research reaffirmed an “underperform” rating on shares of Surmodics in a research report on Friday, November 14th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Surmodics has a consensus rating of “Reduce” and an average price target of $43.00.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).